Drug Delivery Devices Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Drug Delivery Devices Market in 2025 is evaluated at USD 315.95 billion. The global Market size was worth more than USD 301.94 billion in 2024 and is poised to witness a CAGR of over 5.8%, crossing USD 628.4 billion revenue by 2037. North America is anticipated to generate largest share by 2037, driven by increased product releases and initiatives by leading industry participants, along with rising cancer cases in the region.
The growth of the market can be attributed to the increasing worldwide incidence of chronic diseases, and the ongoing efforts to adopt the best vaccines. In accordance to the National Library of Medicine, cardiovascular disease, cancer, chronic lung disease, and diabetes account for one-third of all fatalities worldwide.
Furthermore, increased spending on healthcare improvement is one of the primary reasons driving the growth of the drug delivery devices market. The global spending on healthcare per person increased from USD 864.313 in 2008 to USD 1,110.841 in 2018, with the United States leading the way with a healthcare expenditure of USD 10, 623.85 per capita in 2018.
Drug Delivery Devices Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Need for Targeted Drug Delivery- The growing popularity and importance of digital drug delivery systems among enterprises. Nearly 60 percent of employees in a 5000-person company agree that digital drug delivery technology is critical.
- Growing Technological Advancements- Technological developments in drug delivery systems are expected to make these devices more patient-friendly, easily accessible, and efficient. Phillips-Medisize unveiled its Aria Smart Autoinjector platform in May 2021, enabling breakthroughs, distinction, and long-term viability in the digital drug-delivery device industry.
- Swift Covid-19 Vaccination Drive Globally- With the worldwide epidemic of COVID-19, most pharmaceutical businesses and governments have been and continue to strive toward providing efficient medical care to COVID-19 patients, and drug delivery devices are likely to play an important role in this context. According to Our World in Data, 3.87 million vaccinations are performed internationally every day, with 12.69 billion doses administered globally.
Challenges
- Risk of Needle Stick Injuries
- Increasing Use of Generic Drugs
- Rigorous Rules and Regulations by the Government The government has implemented severe criteria for product testing to assure the product's effectiveness and security. These rigorous rules and regulations may impede the growth of a novel item or the manufacturing of an existing product. As a result, the factor is anticipated to stifle market expansion.
Drug Delivery Devices Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.8% |
|
Base Year Market Size (2024) |
USD 301.94 billion |
|
Forecast Year Market Size (2037) |
USD 628.4 billion |
|
Regional Scope |
|
Drug Delivery Devices Segmentation
Route of Administration (Oral, Transdermal, Injectable)
The injectable segment in the drug delivery devices market is estimated to gain the largest revenue share of about 39% in the year 2037.advances in injectable drug delivery techniques, such as the advent of prefilled syringes and pen injection devices, have boosted demand. Furthermore, the advancement of substances for syringes such as polymers, which are inert to most chemicals, is driving market expansion. In addition, the global vaccination effort, which is increasing syringe use, is expected to contribute to segmental development in the near future. For example, Becton, Dickinson, and Company (BD) announced in 2021 that it had obtained pandemic orders for syringes, and needles totaling 2 billion injectable equipment to support global COVID-19 vaccination initiatives.
Distribution Channel (Hospital, Pharmacies, Surgical Centers)
The hospital segment is expected to garner a significant share of around 30% in the year 2037. Also, the hospital segment had the greatest share in 2022, owing to an increase in cancer, diabetes, and neurological illnesses. Patients hospitalized in the hospital with varied diseases require different pharmaceuticals for therapy, which are administered by various drug delivery approaches. In addition, the availability of contemporary medical equipment, as well as patients' overwhelming desire for receiving care in a hospital setting, are expected to drive category growth.
Our in-depth analysis of the global market includes the following segments:
|
Device Type
|
|
|
Route of Administration
|
|
|
Distribution Channel
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDrug Delivery Devices Industry- Regional Synopsis
North American Market Statistics
The drug delivery devices market in North America, is set to hold a majority of the share accounted to by the end of 2037, owing to the increased product releases and initiatives by leading industry participants. For instance, in accordance to the American Cancer Society's 2022 study, about 1.9 million new cancer cases are projected to be determined in the United States in 2022, the cancer cases are anticipated to rise in the country, which is projected to boost the requirement for drug delivery devices for multiple treatments as requirements for cancer treatment is pretty high in the region as a result of the elevated death rate related to the disease, which is estimated to enhance demand for drug delivery devices for numerous treatment.
European Market Analysis
Further, the Europe drug delivery devices market is estimated to be the second largest, registering a share of about 25% by the end of 2037. Developed economies and acceptable regulatory processes are two of the primary elements generating enormous prospects for the region's leading market competitors. Due to the region's strong economic growth, Asia Pacific is predicted to have the quickest growth rate. Furthermore, a huge patient pool in nations such as Japan, China, and India are driving the use of drug delivery devices by a variety of end-users. Furthermore, in Japan, many sorts of drug delivery systems are being used to deliver specific types of medications. In December 2019, the YpsoMate autoinjector for precise Teribone medicine distribution hit the Japanese market. As a result, the region's increasing usage of sophisticated medication delivery systems is likely to drive market expansion.
Companies Dominating the Drug Delivery Devices Landscape
- Antares Pharma, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Novartis International AG
- Johnson & Johnson
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.,
- Abbott Laboratories
- Cipla Limited
Recent Developments
- Janssen Pharmaceutical Inc., a subsidiary company of Johnson & Johnson announced the FDA approval of drug Darzalex Faspro for the treatment of Multiple Myeloma Cancer.
- IDEAYA Biosciences, Inc. and GlaxoSmithKline plc. announced a strategic partnership to develop solutions in the field of Oncology.
Author Credits: Radhika Pawar
- Report ID: 3868
- Published Date: May 08, 2025
- Report Format: PDF, PPT
